Immunotherapy for Astrocytoma
Active immunotherapy for brain tumors enhances the effect of surgical and radiation treatments, providing an additional attack vector against the tumor.
Active immunotherapy for brain tumors
Astrocytoma is one of the most common primary brain tumors, developing from astrocytes, which are neuroglial cells. Its treatment is mainly based on surgical removal and radiotherapy.
However, when continued tumor growth occurs after surgery and radiation, the prognosis remains extremely poor. In this situation, active immunotherapy provides an additional mechanism for acting on tumor cells and amplifies the effect of standard treatment.
The method was applied to nine patients — children aged 2–7 years — who, after surgery and radiation, exhibited signs of continued tumor growth and had an extremely poor prognosis. All of them received multiple vaccinations.
How the treatment works
Immunotherapy complements the surgical and radiation stages and aims to form a personalized antitumor immune response.
Adjunct to primary treatment
Immunotherapy is integrated after surgical removal and radiotherapy — acting as an additional vector against residual tumor cells.
Adjunct to primary treatment
Immunotherapy is integrated after surgical removal and radiotherapy — acting as an additional vector against residual tumor cells.
Multiple vaccinations
Patients undergo repeated vaccination courses that form and maintain the antitumor immune response.
Multiple vaccinations
Patients undergo repeated vaccination courses that form and maintain the antitumor immune response.
Immune activation
Vaccine-induced immune reactions target the tumor cells and impede their continued growth.
Immune activation
Vaccine-induced immune reactions target the tumor cells and impede their continued growth.
Long-term monitoring
Efficacy is evaluated dynamically over several years by observing the patient's condition.
Long-term monitoring
Efficacy is evaluated dynamically over several years by observing the patient's condition.
Observation Results
Immunotherapy was given to nine children aged 2–7 who retained signs of continued tumor growth after surgery and radiation, and whose prognosis was considered extremely poor.
patients under observation
children aged 2–7 with signs of continued tumor growth
with a distinct clinical effect
the patients were alive and leading full lives
observation period
the results point to the necessity for expanded clinical trials
Method capabilities
Adjunct to standard treatment
Immunotherapy amplifies the impact of surgery and radiotherapy, providing an additional vector against the tumor.
For poor prognosis
A distinct clinical effect was achieved even in patients exhibiting signs of continued tumor growth.
Without severe toxicity
The method is not accompanied by the heavy toxic burden common with chemotherapy and radiation, nor does it limit daily activities.
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.